HEALTHCARE-RESOURCE UTILIZATION RELATED TO THE MANAGEMENT OF C3 GLOMERULOPATHY IN BRAZIL: ANALYSIS FROM THE PUBLIC HEALTHCARE SYSTEM PERSPECTIVE
Author(s)
Jéssica Nacazume, B.Sc.1, Lucas L. Torres, BSc, MSc1, Ana Carolina P. Pereira, MSc2, Enzo W. Asano, B.Sc3, Roberta Arinelli, MSc, MD2;
1Novartis Biociências S.A, São Paulo, Brazil, 2Origin Health, Rio de Janeiro, Brazil, 3Origin Health, São Paulo, Brazil
1Novartis Biociências S.A, São Paulo, Brazil, 2Origin Health, Rio de Janeiro, Brazil, 3Origin Health, São Paulo, Brazil
OBJECTIVES: This study aimed to characterize healthcare resource utilization (HCRU) associated with the management of C3 glomerulopathy (C3G), an ultra-rare disease leading to chronic and progressive kidney damage, from the perspective of the Brazilian public healthcare system (Sistema Único de Saúde).
METHODS: A cross-sectional structured survey was conducted in December 2025 with three nephrologists from different Brazilian regions, all experienced in managing C3G patients in the public healthcare setting. Experts provided practice-based estimates for patients treated over the past year. The survey captured HCRU and disease management patterns across disease stages according to chronic kidney disease (CKD) progression, including outpatient follow-up in specialized care, hospitalizations, and nephrotic syndrome episodes.
RESULTS: Experts estimated that approximately 50% of C3G patients are diagnosed at CKD stages 3 - 4 and 23% at stage 5, requiring renal replacement therapy. While follow-up frequency in specialized care for early stages varied, experts agreed that stage 4 patients typically require at least quarterly nephrology visits, and stage 5 patients monthly visits. Hospitalization burden increased with disease progression, with patients at stages 3 - 5 averaging 1-2 inpatient stays per year, with mean length of stay ranging from 5.8 to 10.5 days per admission. Nephrotic syndrome manifestations were reported in nearly half of patients, with at least one annual episode per patient, adding further complexity to C3G management.
CONCLUSIONS: C3G imposes a significant burden on the Brazilian public healthcare system, with most patients diagnosed at advanced stages of the disease, requiring more intensive follow-up and hospital care. These expert-based HCRU estimates across stages 3-5 highlight the potential value of interventions that could delay disease progression, including strategies for early diagnosis and treatments that can preserve kidney function for longer and potentially reducing the associated resource use and economic impact on public payers.
METHODS: A cross-sectional structured survey was conducted in December 2025 with three nephrologists from different Brazilian regions, all experienced in managing C3G patients in the public healthcare setting. Experts provided practice-based estimates for patients treated over the past year. The survey captured HCRU and disease management patterns across disease stages according to chronic kidney disease (CKD) progression, including outpatient follow-up in specialized care, hospitalizations, and nephrotic syndrome episodes.
RESULTS: Experts estimated that approximately 50% of C3G patients are diagnosed at CKD stages 3 - 4 and 23% at stage 5, requiring renal replacement therapy. While follow-up frequency in specialized care for early stages varied, experts agreed that stage 4 patients typically require at least quarterly nephrology visits, and stage 5 patients monthly visits. Hospitalization burden increased with disease progression, with patients at stages 3 - 5 averaging 1-2 inpatient stays per year, with mean length of stay ranging from 5.8 to 10.5 days per admission. Nephrotic syndrome manifestations were reported in nearly half of patients, with at least one annual episode per patient, adding further complexity to C3G management.
CONCLUSIONS: C3G imposes a significant burden on the Brazilian public healthcare system, with most patients diagnosed at advanced stages of the disease, requiring more intensive follow-up and hospital care. These expert-based HCRU estimates across stages 3-5 highlight the potential value of interventions that could delay disease progression, including strategies for early diagnosis and treatments that can preserve kidney function for longer and potentially reducing the associated resource use and economic impact on public payers.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
EE67
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
SDC: Rare & Orphan Diseases, SDC: Urinary/Kidney Disorders